Trials  ||| S:0 E:7 ||| NNS
with  ||| S:7 E:12 ||| IN
impact  ||| S:12 E:19 ||| NN
on  ||| S:19 E:22 ||| IN
clinical  ||| S:22 E:31 ||| JJ
management ||| S:31 E:41 ||| NN
:  ||| S:41 E:43 ||| :
first  ||| S:43 E:49 ||| JJ
line  ||| S:49 E:54 ||| NN
Advanced-stage  ||| S:54 E:69 ||| JJ
epithelial  ||| S:69 E:80 ||| JJ
ovarian  ||| S:80 E:88 ||| JJ
cancer  ||| S:88 E:95 ||| NN
is  ||| S:95 E:98 ||| VBZ
generally  ||| S:98 E:108 ||| RB
managed  ||| S:108 E:116 ||| VBN
with  ||| S:116 E:121 ||| IN
cytoreductive  ||| S:121 E:135 ||| JJ
surgery  ||| S:135 E:143 ||| NN
and  ||| S:143 E:147 ||| CC
chemotherapy  ||| S:147 E:160 ||| VBP
consisting  ||| S:160 E:171 ||| VBG
of  ||| S:171 E:174 ||| IN
carboplatin  ||| S:174 E:186 ||| NN
and  ||| S:186 E:190 ||| CC
paclitaxel ||| S:190 E:200 ||| NN
.  ||| S:200 E:202 ||| .
Although  ||| S:202 E:211 ||| IN
initially  ||| S:211 E:221 ||| RB
responsive ||| S:221 E:231 ||| JJ
,  ||| S:231 E:233 ||| ,
most  ||| S:233 E:238 ||| RBS
tumors  ||| S:238 E:245 ||| JJ
recur  ||| S:245 E:251 ||| NN
and  ||| S:251 E:255 ||| CC
demonstrate  ||| S:255 E:267 ||| VB
progressive  ||| S:267 E:279 ||| JJ
chemotherapy  ||| S:279 E:292 ||| JJ
resistance ||| S:292 E:302 ||| NN
.  ||| S:302 E:304 ||| .
During  ||| S:304 E:311 ||| IN
the  ||| S:311 E:315 ||| DT
last  ||| S:315 E:320 ||| JJ
20  ||| S:320 E:323 ||| CD
years ||| S:323 E:328 ||| NNS
,  ||| S:328 E:330 ||| ,
many  ||| S:330 E:335 ||| JJ
thousands  ||| S:335 E:345 ||| NNS
of  ||| S:345 E:348 ||| IN
women  ||| S:348 E:354 ||| NNS
have  ||| S:354 E:359 ||| VBP
participated  ||| S:359 E:372 ||| VBN
in  ||| S:372 E:375 ||| IN
international  ||| S:375 E:389 ||| JJ
front-line  ||| S:389 E:400 ||| JJ
phase  ||| S:400 E:406 ||| NN
3  ||| S:406 E:408 ||| CD
trials  ||| S:408 E:415 ||| NNS
that  ||| S:415 E:420 ||| WDT
have  ||| S:420 E:425 ||| VBP
contributed  ||| S:425 E:437 ||| VBN
to  ||| S:437 E:440 ||| TO
our  ||| S:440 E:444 ||| PRP$
understanding  ||| S:444 E:458 ||| NN
of  ||| S:458 E:461 ||| IN
ovarian  ||| S:461 E:469 ||| JJ
cancer  ||| S:469 E:476 ||| NN
biology  ||| S:476 E:484 ||| NN
and  ||| S:484 E:488 ||| CC
helped  ||| S:488 E:495 ||| VBD
to  ||| S:495 E:498 ||| TO
define  ||| S:498 E:505 ||| VB
optimal  ||| S:505 E:513 ||| JJ
treatment  ||| S:513 E:523 ||| NN
strategies ||| S:523 E:533 ||| NNS
.  ||| S:533 E:535 ||| .
Emerging  ||| S:535 E:544 ||| VBG
data  ||| S:544 E:549 ||| NNS
from  ||| S:549 E:554 ||| IN
these  ||| S:554 E:560 ||| DT
trials  ||| S:560 E:567 ||| NNS
need  ||| S:567 E:572 ||| VBP
to  ||| S:572 E:575 ||| TO
be  ||| S:575 E:578 ||| VB
interpreted  ||| S:578 E:590 ||| VBN
within  ||| S:590 E:597 ||| IN
an  ||| S:597 E:600 ||| DT
evolving  ||| S:600 E:609 ||| JJ
paradigm  ||| S:609 E:618 ||| NN
of  ||| S:618 E:621 ||| IN
cancer  ||| S:621 E:628 ||| NN
biology ||| S:628 E:635 ||| NN
,  ||| S:635 E:637 ||| ,
disease  ||| S:637 E:645 ||| NN
management ||| S:645 E:655 ||| NN
,  ||| S:655 E:657 ||| ,
and  ||| S:657 E:661 ||| CC
availability  ||| S:661 E:674 ||| NN
of  ||| S:674 E:677 ||| IN
clinical  ||| S:677 E:686 ||| JJ
resources ||| S:686 E:695 ||| NNS
.  ||| S:695 E:697 ||| .
Survey  ||| S:697 E:704 ||| NN
of  ||| S:704 E:707 ||| IN
recent  ||| S:707 E:714 ||| JJ
phase  ||| S:714 E:720 ||| NN
3  ||| S:720 E:722 ||| CD
trials  ||| S:722 E:729 ||| NNS
and  ||| S:729 E:733 ||| CC
emerging  ||| S:733 E:742 ||| VBG
principles  ||| S:742 E:753 ||| NNS
of  ||| S:753 E:756 ||| IN
ovarian  ||| S:756 E:764 ||| JJ
tumor  ||| S:764 E:770 ||| NN
biology ||| S:770 E:777 ||| NN
.  ||| S:777 E:779 ||| .
There  ||| S:779 E:785 ||| EX
is  ||| S:785 E:788 ||| VBZ
no  ||| S:788 E:791 ||| DT
evidence  ||| S:791 E:800 ||| NN
that  ||| S:800 E:805 ||| IN
adding  ||| S:805 E:812 ||| VBG
a  ||| S:812 E:814 ||| DT
third  ||| S:814 E:820 ||| JJ
cytotoxic  ||| S:820 E:830 ||| JJ
agent  ||| S:830 E:836 ||| NN
improves  ||| S:836 E:845 ||| VBZ
clinical  ||| S:845 E:854 ||| JJ
outcomes ||| S:854 E:862 ||| NNS
.  ||| S:862 E:864 ||| .
However ||| S:864 E:871 ||| RB
,  ||| S:871 E:873 ||| ,
weekly  ||| S:873 E:880 ||| JJ
dose-dense  ||| S:880 E:891 ||| JJ
scheduling  ||| S:891 E:902 ||| NN
of  ||| S:902 E:905 ||| IN
paclitaxel  ||| S:905 E:916 ||| NN
appears  ||| S:916 E:924 ||| VBZ
superior  ||| S:924 E:933 ||| JJ
to  ||| S:933 E:936 ||| TO
standard  ||| S:936 E:945 ||| JJ
dosing ||| S:945 E:951 ||| NN
.  ||| S:951 E:953 ||| .
Primary  ||| S:953 E:961 ||| JJ
therapy  ||| S:961 E:969 ||| NN
with  ||| S:969 E:974 ||| IN
carboplatin  ||| S:974 E:986 ||| NN
and  ||| S:986 E:990 ||| CC
paclitaxel  ||| S:990 E:1001 ||| NN
remains  ||| S:1001 E:1009 ||| VBZ
a  ||| S:1009 E:1011 ||| DT
well-tolerated  ||| S:1011 E:1026 ||| JJ
standard  ||| S:1026 E:1035 ||| JJ
regimen ||| S:1035 E:1042 ||| NN
,  ||| S:1042 E:1044 ||| ,
including  ||| S:1044 E:1054 ||| VBG
the  ||| S:1054 E:1058 ||| DT
option  ||| S:1058 E:1065 ||| NN
of  ||| S:1065 E:1068 ||| IN
weekly  ||| S:1068 E:1075 ||| JJ
paclitaxel  ||| S:1075 E:1086 ||| JJ
dosing ||| S:1086 E:1092 ||| NN
.  ||| S:1092 E:1094 ||| .
Data  ||| S:1094 E:1099 ||| NNS
are  ||| S:1099 E:1103 ||| VBP
awaited  ||| S:1103 E:1111 ||| VBN
from  ||| S:1111 E:1116 ||| IN
completed  ||| S:1116 E:1126 ||| VBN
trials  ||| S:1126 E:1133 ||| NNS
incorporating  ||| S:1133 E:1147 ||| VBG
bevacizumab ||| S:1147 E:1158 ||| NNS
.  ||| S:1158 E:1160 ||| .
Emerging  ||| S:1160 E:1169 ||| VBG
biological  ||| S:1169 E:1180 ||| JJ
paradigms  ||| S:1180 E:1190 ||| NN
will  ||| S:1190 E:1195 ||| MD
contribute  ||| S:1195 E:1206 ||| VB
to  ||| S:1206 E:1209 ||| TO
individualized  ||| S:1209 E:1224 ||| VB
treatment  ||| S:1224 E:1234 ||| NN
options  ||| S:1234 E:1242 ||| NNS
in  ||| S:1242 E:1245 ||| IN
the  ||| S:1245 E:1249 ||| DT
future ||| S:1249 E:1255 ||| NN
.  ||| S:1255 E:1257 ||| .
